Due to the number of contributing authors, the affiliations are provided in the Supplemental Material .
Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1795-1803. doi: 10.2215/CJN.03950417. Epub 2017 Aug 7.
Anemia is an early complication of CKD that is associated with increased morbidity and mortality. Prior data show associations between abnormal mineral metabolism markers and decreased erythropoiesis. However, few studies have investigated elevated fibroblast growth factor 23 as a risk factor for the development of anemia in patients with CKD.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a prospective cohort study of 3869 individuals with mild to severe CKD enrolled in the Chronic Renal Insufficiency Cohort Study between 2003 and 2008 and followed through 2013. We hypothesized that elevated baseline fibroblast growth factor 23 levels are associated with prevalent anemia, decline in hemoglobin over time, and development of incident anemia, defined as serum hemoglobin level <13 g/dl in men, serum hemoglobin level <12 g/dl in women, or use of erythropoietin stimulating agents.
In the 1872 of 3869 individuals who had prevalent anemia at baseline, mean age was 58 (11) years old, and mean eGFR was 39 (13) ml/min per 1.73 m. Higher levels of fibroblast growth factor 23 were significantly associated with prevalent anemia (odds ratio per 1-SD increase in natural log-transformed fibroblast growth factor 23, 1.39; 95% confidence interval, 1.26 to 1.52), decline in hemoglobin over 4 years, and risk of incident anemia (hazard ratio per 1-SD increase in natural log-transformed fibroblast growth factor 23, 1.13; 95% confidence interval, 1.04 to 1.24; quartile 4 versus quartile 1: hazard ratio, 1.59; 95% confidence interval, 1.19 to 2.11) independent of demographic characteristics, cardiovascular disease risk factors, CKD-specific factors, and other mineral metabolism markers. The results of our prospective analyses remained unchanged after additional adjustment for time-varying eGFR.
Elevated fibroblast growth factor 23 is associated with prevalent anemia, change in hemoglobin over time, and development of anemia. Future studies are needed to elucidate the mechanisms for these associations.
贫血是 CKD 的早期并发症,与发病率和死亡率的增加有关。先前的数据表明,异常的矿物质代谢标志物与红细胞生成减少之间存在关联。然而,很少有研究调查过升高的成纤维细胞生长因子 23 作为 CKD 患者贫血发展的危险因素。
设计、设置、参与者和测量:我们对 2003 年至 2008 年间参加慢性肾功能不全队列研究并随访至 2013 年的 3869 名轻度至重度 CKD 患者进行了一项前瞻性队列研究。我们假设基线时升高的成纤维细胞生长因子 23 水平与现患贫血、血红蛋白随时间下降以及贫血事件的发生有关,贫血事件定义为男性血清血红蛋白水平<13g/dl、女性血清血红蛋白水平<12g/dl 或使用红细胞生成素刺激剂。
在 3869 名基线时现患贫血的患者中,有 1872 名患者的平均年龄为 58(11)岁,平均 eGFR 为 39(13)ml/min/1.73m。成纤维细胞生长因子 23 水平升高与现患贫血显著相关(自然对数转换后的成纤维细胞生长因子 23 每增加 1-SD,比值比为 1.39;95%置信区间为 1.26 至 1.52),血红蛋白在 4 年内下降,以及贫血事件的风险(自然对数转换后的成纤维细胞生长因子 23 每增加 1-SD,风险比为 1.13;95%置信区间为 1.04 至 1.24;四分位间距 4 与四分位间距 1:风险比为 1.59;95%置信区间为 1.19 至 2.11),独立于人口统计学特征、心血管疾病危险因素、CKD 特定因素和其他矿物质代谢标志物。在对时变 eGFR 进行额外调整后,我们的前瞻性分析结果仍然不变。
升高的成纤维细胞生长因子 23 与现患贫血、血红蛋白随时间变化以及贫血的发生有关。需要进一步的研究来阐明这些关联的机制。